find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
60
Clinical Trials
Lymphoma
NA
Accepting Patients
nct/study# NCT03711604 / RP6530-1803
An Open Label, Compassionate Use Study Of Tenalisib (RP6530) In Patients Currently Receiving Treatment On Tenalisib Trials In Hematological Malignancies
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT02628405 / RU051417I
Phase I/II, Open-Label Study Of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) In Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2021-0328
Patient Characteristics And Outcomes In Lymphoma With Pre-Existing Autoimmune Diseases.
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2021-0512
Clinical Efficacy And Mechanisms Of Resistance To Polatuzumab Vedotin In Patients With Large B-Cell Lymphoma After CAR T-Cell Therapy
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / PROCLIP
Prospective Multicenter International Observational Study For Determination Of A Cutaneous Lymphoma International Prognostic Index Model And Impact Of Major Therapies In Patients With Advanced Mycosis Fungoides And Sézary Syndrome Advanced Stage PROCLIPI Project By The Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2020-1089
Comparison Of Clinical Trials Enrollment In Patient Records And Claims
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.